Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0014070 (
encephalomyelitis
)
13,017
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lipocalin-2
(
LCN2
) plays an important role in cellular processes as diverse as cell growth, migration/invasion, differentiation, and death/survival. Furthermore, recent studies indicate that
LCN2
expression and secretion by glial cells are induced by inflammatory stimuli in the central nervous system. The present study was undertaken to examine the regulation of
LCN2
expression in experimental autoimmune
encephalomyelitis
(EAE) and to determine the role of
LCN2
in the disease process.
LCN2
expression was found to be strongly increased in spinal cord and secondary lymphoid tissues after EAE induction. In spinal cords astrocytes and microglia were the major cell types expressing
LCN2
and its receptor 24p3R, respectively, whereas in spleens,
LCN2
and 24p3R were highly expressed in neutrophils and dendritic cells, respectively. Furthermore, disease severity, inflammatory infiltration, demyelination, glial activation, the expression of inflammatory mediators, and the proliferation of MOG-specific T cells were significantly attenuated in Lcn2-deficient mice as compared with wild-type animals. Myelin oligodendrocyte glycoprotein-specific T cells in culture exhibited an increased expression of Il17a, Ifng, Rorc, and Tbet after treatment with recombinant LCN2 protein. Moreover,
LCN2
-treated glial cells expressed higher levels of proinflammatory cytokines, chemokines, and MMP-9. Adoptive transfer and recombinant LCN2 protein injection experiments suggested that
LCN2
expression in spinal cord and peripheral immune organs contributes to EAE development. Taken together, these results imply
LCN2
is a critical mediator of autoimmune inflammation and disease development in EAE and suggest that
LCN2
be regarded a potential therapeutic target in multiple sclerosis.
...
PMID:Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues. 2480 82
Lipocalin-2
(
LCN2
) is a key mediator of various cellular processes. Recent studies have indicated that
LCN2
also plays an important role in central nervous system (CNS) injuries and neurological diseases, such as spinal cord injury, stroke, experimental autoimmune
encephalomyelitis
, and neurodegenerative diseases. Here, we investigated the role of
LCN2
in a rodent model of lipopolysaccharide (LPS)-induced neuroinflammation. At 24 hours after intraperitoneal injection of LPS,
LCN2
expression was strongly induced in the brain;
LCN2
was mainly expressed in endothelial cells, astrocytes, and microglia. Next, we used
LCN2
-deficient mice to further investigate the role of
LCN2
in neuroinflammation.
LCN2
deficiency attenuated LPS-induced glial activation in the brain. In a mechanistic study employing glia/neuron co-cultures,
LCN2
deficiency reduced glial neurotoxicity. Our results indicate that
LCN2
plays a central role in the neuroinflammatory responses following LPS administration, and that
LCN2
might contribute to the uncontrolled neurotoxic glial activation under excessive and chronic inflammatory conditions.
...
PMID:Lipocalin-2 Acts as a Neuroinflammatogen in Lipopolysaccharide-injected Mice. 2496 80